Sionna Therapeutics is trading 5.01% up now at $5.55 after a volatile selloff over the preceding week.
- No credible August 24, 2026 company announcement directly explains the gain; latest company-specific coverage concerns an investor-law-firm investigation following the failed SION-719 Phase 2a trial.
- The broader market is mixed rather than strongly risk-on, so the move appears most consistent with a short-term rebound or volatility after the earlier collapse, not a confirmed fundamental catalyst.